Peptide Therapeutics Market Size, Share, Growth, Trend Analysis and Industry Research Report
The
global peptide therapeutics market is expected to reach
USD 48.04 billion by 2025, according to a new report by Grand View Research,
Inc. Increasing demand for efficient & rapid-acting therapeutics for
treatment of cancer and other lifestyle-associated disorders, which result in
lesser adverse effects, are anticipated to propel market growth.
Rising
incidence of cancer calls for exploring and introducing other means of
therapies and low-cost treatment alternatives. Moreover, growing base of
geriatric population is expected to widen the consumer base by triggering
incidence rate of target diseases such as cancer & diabetes, which are
expected to drive the demand for peptide therapeutics.
Technological
advancements in peptide manufacturing process is one of the major factors
driving the market growth during the forecast period. Manufacturers and
suppliers are focusing on the adoption of novel technologies to manufacture
efficient drug molecules with low time and capital investment. Improvement in
purification & automation process and less generation of waste is an
additional factor attributing toward market growth
Further Key
Findings from the Study Suggest:
- Cancer held the
largest market share in 2016 owing to increasing demand for alternative
therapeutics over conventional treatment options. Peptides are being used
as potential therapeutic agents in cancer treatment.
- The generic
drug segment is expected to showcase upward shift due to patent expiration
of blockbuster peptides and supportive government initiatives pertaining
to the introduction of generic class
- Outsourced
manufacturing is expected to grow at CAGR of 6.7% owing to requirements of
complex procedures and shift in preference toward outsourcing, which helps
in eliminating cost of production.
- Route of
administration including nasal and intradermal routes is expected to grow
at a rapid pace owing to ease of usage and advantages over other routes of
administration such as oral.
- Hybrid
technology is expected to spearhead the growth of this market. Benefits
associated with this technology such as time conservation and ease of
usage for both solid- and liquid-phase peptide synthesis are the key
factors affirming growth.
- North America
held the largest share in terms of revenue in 2016 owing to higher level
of awareness pertaining to genomics & proteomics products,
well-established R&D infrastructure, and rising funding initiatives
- Asia Pacific
industry is expected to showcase lucrative growth over the forecast period
with CAGR of 11.0%. Presence of established generic industry and API
providers in this region coupled with growing economic stability in some
of the countries is expected to propel market growth.
- Some of the key
players in the peptide therapeutics market include Eli Lilly and Company;
Pfizer, Inc.; Amgen, Inc.; Takeda Pharmaceutical Company Limited; Teva
Pharmaceuticals Industries Ltd.; Lonza Inc.; Sanofi; Bristol-Myers Squibb
(BMS); AstraZeneca PLC; GlaxoSmithKline plc (GSK); Novartis AG; and Novo
Nordisk A/S
Access full
research report on global peptide therapeutics market:
www.grandviewresearch.com/industry-analysis/peptide-therapeutics-market
Comments